Study summary · research use only
Combining RNA-seq, molecular docking and experimental verification to explore the mechanism of BAM15 as a potential drug for atherosclerosis
Plain-language summary
Paraphrased from the published abstract below — not a verdict on whether anything works.
In this study using ApoE(-/-) mice fed a western diet, and in vitro RAW264.7 mouse macrophages, the authors investigated BAM15, a mitochondrial uncoupling agent, in relation to atherosclerosis (AS), combining RNA-seq, molecular docking, and experimental work. Oral BAM15 was reported to suppress atherosclerosis in the mice and to reduce elevated serum ALT, AST, and liver TC, TG, ALT, and AST. In vitro, BAM15 was reported to inhibit RAW264.7 macrophage invasive ability and reduce palmitic acid-induced lipid accumulation. RNA-seq identified differentially expressed genes after BAM15 treatment, with 140 shared targets identified against AS-related targets; a protein-protein interaction network highlighted IL1A, SRC, and CSF3, further verified by molecular docking and western blot, and molecular dynamics analysis reported strong affinity between BAM15 and the IL-1α, SRC and CSF3 proteins.
Abstract
BAM15 is a novel mitochondrial uncoupling agent derived from a synthetic source, that has been wildly explored for its ability to enhance mitochondrial respiration and metabolic flexibility. In this study, we investigated the underlying mechanisms of BAM15 on atherosclerosis (AS) through experimental validation, RNA-seq and molecular docking. The results showed that oral administration of BAM15 suppressed atherosclerosis in western diet (WD)-fed ApoE(-/-) mice and significantly improved the hyperlipidemia. And the increased serum ALT, AST and liver TC, TG, ALT, AST in ApoE(-/-) mice were reduced by BAM15 treatment. In in vitro experiments BAM15 inhibited RAW264.7 macrophages invasive ability and reduced palmitic acid-induced lipid accumulation. RNA-seq results confirmed the differential genes after BAM15 treatment and 140 common targets were identified by intersecting with AS-related targets. A protein-protein interaction (PPI) network analysis high-lighted IL1A, SRC and CSF3 as key targets of BAM15 against AS, which is further verified by molecular docking and western blot. Molecular dynamics analysis results confirmed that BAM15 exhibits strong affinity with the IL-1α, SRC and CSF3 proteins. This study indicates that BAM15 inhibits atherosclerosis through a multi-molecular mechanism, and we propose it as a novel anti-atherosclerotic drug.
pepmg summarizes the peer-reviewed literature and links to every source — it sells nothing, ships nothing, and gives no medical, dosing, or human-use guidance. Don't just trust this summary: follow the citation to its source and read it yourself. Research use only.